<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="846">
  <stage>Registered</stage>
  <submitdate>15/09/2005</submitdate>
  <approvaldate>15/09/2005</approvaldate>
  <nctid>NCT00197184</nctid>
  <trial_identification>
    <studytitle>Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared</studytitle>
    <scientifictitle>Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix Vaccine, Administered According to a 0,6 Month Schedule and a 0,1,6 Month Schedule, in Healthy Children Aged Between 1-11 Years at the Time of First Vaccine Dose</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>208127/133 (EXT Y3)</secondaryid>
    <secondaryid>208127/132 (EXT Y2)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <healthcondition>Hepatitis A</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Twinrix Adult
Other interventions - Twinrix Junior

Experimental: Twinrix Junior - Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).

Active Comparator: Twinrix Adult - Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).


Other interventions: Twinrix Adult
Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.

Other interventions: Twinrix Junior
Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anti-hepatitis A (HAV) Antibody Concentrations - Geometric mean concentration for anti-HAV antibodies expressed as Milli-International Units per milliliter (mIU/mL)</outcome>
      <timepoint>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-hepatitis B (HBs) Antibody Concentrations - Geometric mean concentration for anti-HBs antibodies expressed as Milli-International Units per milliliter (mIU/mL).</outcome>
      <timepoint>Year 2 (Month 24), Year 3 (Month 36), Year 4 (Month 48) and Year 5 (Month 60)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose. - Any subjects becoming seronegative for anti-HAV antibodies (i.e. titres &lt; 15 mIU/ml) at any long term time point, were to receive an additional vaccine dose administered between 6 to 12 months after Year 5 time point.</outcome>
      <timepoint>Before and one month after additional vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose. - Subjects losing seroprotective anti-HBs antibody titres (i.e. titres &lt; 10 mIU/ml) at any long term time point, received an Engerix challenge dose. The table presents the geometric mean concentrations for anti-HBs antibodies, expressed as Milli-International Units per milliliter (mIU/mL).</outcome>
      <timepoint>Before and One month after additional vaccination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy. - A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</outcome>
      <timepoint>From last study visit of the primary study up to Year 5 long term follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms - Solicited local symptoms assessed include pain, redness and swelling at the vaccine injection site.
Any= regardless of intensity grade; Grade 3 Pain= spontaneously painful</outcome>
      <timepoint>during the 4-day follow-up period after additional vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms. - Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.
Any= regardless of intensity grade or relationship to vaccination; grade 3= prevented normal activity; Related= considered by the investigator to be causally related to the vaccination</outcome>
      <timepoint>During the 4-day follow-up period after additional vaccination</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs). - An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</outcome>
      <timepoint>During the 30-day follow-up period after additional vaccination.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events - A serious adverse event (SAE) is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</outcome>
      <timepoint>At least one month after additional vaccination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participation in primary study

          -  Written informed consent obtained before each long term follow up visit.</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>13</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>276</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>GSK Investigational Site - North Adelaide</hospital>
    <hospital>GSK Investigational Site - Carlton</hospital>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3053 - Carlton</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Blanes (Girona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cerdanyola del Vall√©s / Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the persistence of anti-hepatitis A virus (HAV) and anti-hepatitis B surface
      antigen (HBs) antibodies up to 2, 3, 4 and 5 years after administration of the first dose of
      the study vaccine.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00197184</trialwebsite>
    <publication>Marshall H, Nolan T, D√≠ez Domingo J, Rombo L, Sokal EM, Mar√®s J, Casanovas JM, Kuriyakose S, Leyssen M, Jacquet JM. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine. 2010 Jun 17;28(27):4411-5. doi: 10.1016/j.vaccine.2010.04.040. Epub 2010 Apr 29.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>